Targeting the miR-630/YAP1/ERK feedback loop in epidermal growth factor receptor-mutated lung adenocarcinomas

Lung cancer is the most prevalent cancer type globally. Over 1.8 million new cases are diagnosed and 1.6 million deaths are reported yearly. The 5-year survival rates of lung cancer vary in different disease stages, histological types, genders and regions. Early screening, detection and treatment are helpful to improve survival rates (1). In the last few years, targeted therapy is becoming a promising strategy for advanced lung cancer patients.